METAspread

Need

An important challenge for clinical oncologists in detecting metastatic colorectal cancer (mCRC) is the need for non-invasive, more sensitive and specific biomarkers that reliably identify metastases in early stages. Despite advances in imaging technologies and liquid biopsies, there are still limitations in accurately detecting micrometastases or minimal residual disease, key aspects for timely and effective treatment planning. Early detection methods for metastatic diseases remain insufficient. Additionally, screening programs are often not comprehensive enough, leading to many cases being diagnosed in advanced stages.

Solution

The METAspread test proposes an innovative solution to overcome current limitations in detecting colorectal cancer (CRC) metastasis through a lateral flow assay (LFA) in urine. Based on the quantification of 3 specific biomarkers—trimethylamine oxide (TMAO), cis-aconitate, and valine (patent pending)—it has demonstrated an overall accuracy of 86% (83% sensitivity and 87% specificity), validated with 800 samples.

The main advantage of METAspread is that it is a non-invasive test and allows for monitoring, reducing dependence on imaging tests and invasive procedures, which decreases healthcare costs. It is fast and practical; it can be performed quickly in both clinical settings and at home, with the ability for early detection and real-time monitoring. Moreover, its ease of use makes it applicable in resource-limited settings. Early detection of metastasis allows for treatment adjustment and improved survival, avoiding unnecessary overtreatment in the absence of metastasis. METAspread combines sensitivity and practicality to improve the diagnosis of metastatic CRC.

Goal

To improve the detection of colorectal cancer (CRC) metastasis through a non-invasive, highly specific, sensitive, and practical urine test.